Synthesis of specifically deuterated adenosine A 1  antagonist: BG9928 | Zendy

Conlon Patrick R. | Zendy; Kiesman William F. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Synthesis of specifically deuterated adenosine A 1 antagonist: BG9928

Author(s) -

Conlon Patrick R.,

Kiesman William F.

Publication year - 2007

Publication title -

journal of labelled compounds and radiopharmaceuticals

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.432

H-Index - 47

eISSN - 1099-1344

pISSN - 0362-4803

DOI - 10.1002/jlcr.1237

Subject(s) - chemistry , bicyclic molecule , antagonist , in vivo , pyrimidine , octane , adenosine , stereochemistry , deuterium , biochemistry , organic chemistry , receptor , physics , microbiology and biotechnology , quantum mechanics , biology

BG9928, a high affinity adenosine A 1 antagonist, is currently in Phase II clinical trials for the treatment of congestive heart failure. A deuterium‐labeled version of the molecule was synthesized and used as a standard for in vivo pharmacokinetic and in vitro metabolism studies. The labeled form of 3‐[4‐(2,6‐dioxo‐1,3‐dipropyl‐2,3,6,7‐tetrahydro‐1 H ‐purin‐8‐yl)‐bicyclo[2.2.2]oct‐1‐yl]‐propionic acid (BG9928) was obtained in a convergent manner by joining two major building blocks: the specifically labeled heterocycle 5,6‐diamino‐1,3‐dipropyl‐1 H ‐pyrimidine‐2,4‐dione ( 4 ) and the hemiester 4‐(2‐methoxycarbonyl‐ethyl)‐bicyclo[2.2.2]octane‐1‐carboxylic acid ( 10 ). Copyright © 2007 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research